Recently, the treatment of bacterial infections has become more difficult due to a significant increase in bacterial resistance to the antibiotics including the venerable beta-lactam class of antibiotics.   Beta-lactamase inhibitors restore the efficacy of antibacterials against pathogens that have evolved immunity to treatment over time by disrupting the central mode of bacterial resistance, namely the production of beta-lactamases.   MK-7655, currently in clinical trials for the treatment of bacterial infection, is a potent and irreversible inhibitor of beta-lactamases.  Herein, we report the development of a practical and cost-effective manufacturing route for the synthesis of MK-7655.

Development of a manufacturing route for the synthesis of a beta-lactamase inhibitor MK-7655

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.